Stock Events

Stock Events

Search...

Cg Oncology

$63.96

0

-$1.38-2.11% Tuesday 05:36

Statistics

Day High

63.96

Day Low

63.96

52W High

-

52W Low

-

Volume

2

Avg. Volume

-

Mkt Cap

5.4B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

7MayExpected

Q3 2025

Q4 2025

Next

-0.6

-0.58

-0.57

-0.55

Expected EPS

-0.555732

Actual EPS

N/A

Financials

-3,985.02%Profit Margin

Unprofitable

2021

2022

2023

2024

2025

8.08MRevenue

-321.99MNet Income

Analyst Ratings

$76.33Average Price Target

The highest estimate is 90.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGON.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in developing cancer immunotherapies, directly competing in the oncology space.

Merck is known for its strong portfolio in oncology, including immunotherapy drugs that compete in similar markets as CG Oncology.

Pfizer has a broad range of cancer treatments, including vaccines and advanced biologics, competing in the oncology sector.

AstraZeneca focuses on various cancer drugs, including those for conditions directly targeted by CG Oncology's pipeline.

Gilead Sciences

Gilead Sciences, through its acquisition of Kite Pharma, has become a significant player in the cancer therapy field, overlapping with CG Oncology's focus areas.

Novartis offers advanced cancer treatments, including gene therapy and immunotherapy, competing in the same therapeutic areas as CG Oncology.

Amgen develops targeted therapies and immunotherapies for cancer, aligning them as a competitor in the oncology market.

Roche Holding AG, with its extensive cancer drug portfolio, competes directly in the oncology market, impacting CG Oncology's market share.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals focuses on innovative biologics in oncology, which competes with CG Oncology's approach to cancer treatment.

Exelixis is involved in the discovery, development, and commercialization of new cancer therapies, competing in similar therapeutic areas as CG Oncology.

About

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Show more...

CEO

ISIN

US1569441009

Listings

0 Comments

Share your thoughts

FAQ

What is Cg Oncology stock price today?▼

The current price of CGON.BOATS is $63.96 USD — it has decreased by -2.11% in the past 24 hours. Watch Cg Oncology stock price performance more closely on the chart.

What is Cg Oncology stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Cg Oncology stocks are traded under the ticker CGON.BOATS.

What is Cg Oncology market cap?▼

Today Cg Oncology has the market capitalization of 5.4B

When is the next Cg Oncology earnings date?▼

Cg Oncology is going to release the next earnings report on May 07, 2026.

What were Cg Oncology earnings last quarter?▼

CGON.BOATS earnings for the last quarter are -0.55 USD per share, whereas the estimation was -0.6 USD resulting in a +8.39% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Cg Oncology revenue for the last year?▼

Cg Oncology revenue for the last year amounts to 8.08M USD.

What is Cg Oncology net income for the last year?▼

CGON.BOATS net income for the last year is -321.99M USD.

When did Cg Oncology complete a stock split?▼

Cg Oncology has not had any recent stock splits.